Drug Insights

Effortless Searching: How to Find Methylphenidate on Synapse

11 February 2024
2 min read

Methylphenidate hydrochloride, a preeminent central nervous system (CNS) stimulant, which was initially sanctioned by the United States on the 5th of December, 1955, and skillfully engineered by the pharmacological powerhouse Novartis, is an efficacious medication that ameliorates the symptoms of narcolepsy, attention deficit disorder (ADD), and attention deficit disorder with hyperactivity (ADHD). The intricate mechanism by which this complex pharmacological agent operates is by augmenting the levels of neurotransmitters, specifically norepinephrine and dopamine, within the brain, which results in improved concentration, attentiveness, and a reduction in impulsive behavior. This pharmacological compound, which is also marketed under the brand names Ritalin and Concerta, is classified by its intricate chemical structure, namely methyl α-phenyl-2-piperidineacetate hydrochloride. Despite its status as a frequently prescribed medication for ADHD, the use of methylphenidate hydrochloride may produce a range of deleterious side effects such as appetite loss, insomnia, and anxiety, underscoring the imperative for the usage of this medication to be judiciously guided by the expertise of a healthcare professional. Click on the image below to begin the exploration journey of Methylphenidate through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

4DMT's Study Shows Promising Outcomes for Eye Injection 4D-150 in Treating Wet Age-Related Macular Degeneration
Latest Hotspot
3 min read
4DMT's Study Shows Promising Outcomes for Eye Injection 4D-150 in Treating Wet Age-Related Macular Degeneration
11 February 2024
4DMT Unveils Encouraging Early Results of the Phase 2 PRISM Study for the Eye Injection 4D-150, Indicating Good Safety and Efficacy in Treating Wet Age-Related Macular Degeneration.
Read →
Making the Most Out of Synapse: Searching for Carvedilol
Drug Insights
2 min read
Making the Most Out of Synapse: Searching for Carvedilol
11 February 2024
Carvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990.
Read →
Inmagene Activates Its Right to Secure Sole Global Licensing for IMG-007 and IMG-004 from HUTCHMED
Latest Hotspot
3 min read
Inmagene Activates Its Right to Secure Sole Global Licensing for IMG-007 and IMG-004 from HUTCHMED
11 February 2024
Inmagene Biopharmaceuticals has announced its intention to acquire a solo, global license with royalties for IMG-007, a non-eliminating humanized antibody targeting OX40, and IMG-004, a systemically administered BTK inhibitor with non-covalent, reversible mechanisms.
Read →
Synapse Simplified: How to Find Lamotrigine Information
Drug Insights
2 min read
Synapse Simplified: How to Find Lamotrigine Information
11 February 2024
Lamotrigine, approved by the US FDA on Dec 27, 1994, is a leading anticonvulsant drug developed by GlaxoSmithKline.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.